Obergan (Rivaroxaban)

Rivaroxaban, the active ingredient in Obergan, is a direct Factor Xa inhibitor presented as a tablet for oral use. It is indicated for the prevention and treatment of thromboembolic disorders in adult patients. GNH USA supplies Obergan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Obergan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rivaroxaban is an oral anticoagulant that acts on the coagulation cascade to reduce clot formation in several clinical settings.

- Atrial fibrillation: reduces the risk of stroke and systemic embolism in patients with non‑valvular atrial fibrillation. - Deep‑vein thrombosis (DVT) treatment: treats acute DVT and helps prevent recurrence. - Pulmonary embolism (PE) treatment: treats acute PE and helps prevent recurrence. - Post‑operative thromboprophylaxis: prevents venous thromboembolism after hip or knee replacement surgery. - Secondary prevention after myocardial infarction: lowers the risk of subsequent cardiovascular events.

Rivaroxaban may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Minor gastrointestinal discomfort or dyspepsia. - Mild bruising or superficial skin ecchymoses. - Transient headache. - Nausea. - Low‑grade elevation of liver enzymes.

Serious or Rare Side Effects: - Major bleeding, including intracranial or gastrointestinal hemorrhage. - Hemorrhagic stroke. - Spontaneous retroperitoneal bleed. - Severe allergic reactions such as anaphylaxis. - Liver injury with marked enzyme elevation. - Thrombocytopenia.

When prescribing rivaroxaban, clinicians should assess individual risk factors and monitor patients for signs of bleeding.

- Renal impairment: adjust dose or avoid use in severe renal dysfunction. - Hepatic disease: avoid in patients with significant liver disease. - Concomitant antiplatelet therapy: increase bleeding risk; use caution. - History of gastrointestinal ulcer or bleeding: monitor closely. - Pregnancy and lactation: avoid unless clearly needed; discuss risks. - Store at below 25°C: keep in the original container, protect from moisture and light.

Rivaroxaban interacts with several drug classes that can modify its anticoagulant effect, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may substantially reduce efficacy. - Combined use with other anticoagulants or antiplatelet agents: high risk of serious bleeding.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin): may modestly raise rivarox‑an levels. - NSAIDs and selective COX‑2 inhibitors: increase gastrointestinal bleeding risk. - P‑gp inhibitors (e.g., amiodarone, verapamil): can elevate drug exposure. - Herbal supplements such as St John’s wort: may reduce anticoagulant effect. - Antifungal azoles (e.g., fluconazole): may increase exposure modestly.